全文获取类型
收费全文 | 3798篇 |
免费 | 501篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 6篇 |
妇产科学 | 7篇 |
基础医学 | 277篇 |
口腔科学 | 22篇 |
临床医学 | 177篇 |
内科学 | 105篇 |
皮肤病学 | 2599篇 |
神经病学 | 8篇 |
特种医学 | 29篇 |
外科学 | 45篇 |
综合类 | 430篇 |
现状与发展 | 1篇 |
预防医学 | 37篇 |
眼科学 | 7篇 |
药学 | 350篇 |
1篇 | |
中国医学 | 230篇 |
肿瘤学 | 23篇 |
出版年
2024年 | 4篇 |
2023年 | 114篇 |
2022年 | 100篇 |
2021年 | 188篇 |
2020年 | 247篇 |
2019年 | 204篇 |
2018年 | 167篇 |
2017年 | 183篇 |
2016年 | 167篇 |
2015年 | 133篇 |
2014年 | 238篇 |
2013年 | 300篇 |
2012年 | 163篇 |
2011年 | 167篇 |
2010年 | 202篇 |
2009年 | 193篇 |
2008年 | 182篇 |
2007年 | 164篇 |
2006年 | 174篇 |
2005年 | 144篇 |
2004年 | 140篇 |
2003年 | 140篇 |
2002年 | 101篇 |
2001年 | 92篇 |
2000年 | 76篇 |
1999年 | 70篇 |
1998年 | 34篇 |
1997年 | 38篇 |
1996年 | 30篇 |
1995年 | 36篇 |
1994年 | 24篇 |
1993年 | 21篇 |
1992年 | 17篇 |
1991年 | 10篇 |
1990年 | 15篇 |
1989年 | 11篇 |
1988年 | 15篇 |
1987年 | 13篇 |
1986年 | 7篇 |
1985年 | 4篇 |
1984年 | 12篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 4篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1973年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有4359条查询结果,搜索用时 31 毫秒
61.
《Expert Review of Clinical Immunology》2013,9(10):949-958
TNF inhibitors and anti-p40IL12/23 monoclonal antibodies are efficacious treatments for moderate-to-severe psoriasis. However, the formation of anti-drug antibodies (ADA) with biologics may prevent patients from achieving a full clinical response. ADA have been reported in patients treated with etanercept, infliximab, adalimumab or ustekinumab at rates of 0–18.3%, 5.4–43.6%, 8.8–44.8% and 3.8–5.4%, respectively. Antibodies against etanercept have no apparent effects on clinical response, whereas antibodies against infliximab or adalimumab have been associated with diminished clinical response. The significance of ADA against ustekinumab is yet to be determined. Data regarding management strategies to counteract ADA formation and their effects are limited in psoriasis patients. However, some evidence suggests that concomitant immunomodulators such as methotrexate may suppress ADA development in psoriasis. ADA specific to one biologic do not appear to carry cross-linking potential with other biologic agents. ADA formation needs to be considered as a possible factor contributing to diminished response from biologic agents. 相似文献
62.
《Expert Review of Clinical Immunology》2013,9(6):789-800
Celiac disease (CD) is an autoimmune gluten-dependent enteropathy characterized by atrophy of the intestinal villi that improves after a gluten-free diet. CD is often associated with extraintestinal manifestations. In the past few years, growing evidence has documented the involvement of skin diseases among the extraintestinal manifestations of CD. This association could be related to the impairment of intestinal absorption and motility, other than to immunological and hormonal changes. The aim of this review is to report all CD-associated skin manifestations described in the literature and to analyze the possible mechanisms involved in this association. The opportunity to evaluate the possible presence of CD in patients affected by skin disorders is discussed. 相似文献
63.
Burak Tekin MD Mehmet Salih Gurel MD Zeynep Topkarci MD Filiz Topaloglu Demir MD Sema Aytekin MD Filiz Cebeci Kahraman MD Ralfi Singer MD Vefa Asli Erdemir MD Tugba Kevser Uzuncakmak MD Sirin Yasar MD Necmettin Akdeniz MD Ilknur Kivanc Altunay MD Emek Kocaturk MD Zafer Turkoglu MD Bilgen Erdogan MD 《Pediatric dermatology》2018,35(5):651-659
64.
Maria Carlström Anna‐Karin Ekman Stina Petersson Peter Söderkvist Charlotta Enerbäck 《Experimental dermatology》2012,21(12):932-937
NACHT leucine‐rich repeat‐ and PYD‐containing (NLRP)3 protein controls the inflammasome by regulating caspase‐1 activity and interleukin (IL)‐1β processing. The contribution of IL‐1β in the pathogenesis of psoriasis is well recognized. Polymorphisms in NLRP3 and caspase recruitment domain–containing protein (CARD)8, a negative regulator of caspase‐1 activity, have been associated with susceptibility to common inflammatory diseases, such as Crohn's disease and rheumatoid arthritis. To investigate the role for genetic variants in the NLRP3 inflammasome in psoriasis susceptibility. In a patient sample comprising 1988 individuals from 491 families and 1002 healthy controls, genotypes for four selected single‐nucleotide polymorphisms (SNPs) in NLRP3 (three SNPs) and CARD8 (one SNP) were determined by TaqMan® Allelic Discrimination. Using the transmission disequilibrium test (TDT), a significant increase in the transmission of the NLRP3 rs10733113G genotype to a subgroup of patients with more widespread psoriasis was demonstrated (P = 0.015). Using logistic regression analysis in 741 patients with psoriasis and 1002 controls, the CARD8 rs2043211 genotype was significantly different in cases and controls in overall terms [OR 1.3 (1.1–1.5), P = 0.004] and for both genders. Our data support the hypothesis that the inflammasome plays a role in psoriasis susceptibility. 相似文献
65.
66.
Claudia Günther Kristin Blau Ulrike Förster Antje Viehweg Gottfried Wozel Knut Schäkel 《Experimental dermatology》2013,22(8):535-540
Dermal dendritic cells (DCs) play a central role in the immunopathology of psoriasis. We previously identified slanDCs as pro‐inflammatory TNF‐α, IL‐23‐ and IL‐12‐producing DCs in human blood and as prominent inflammatory dermal TNF‐α secreting and CD11c‐positive DC subset in psoriasis. Here, we ask for the effects of TNF‐α‐inhibition on inflammatory slanDCs in skin and blood of 10 patients with psoriasis during 24 weeks of treatment with etanercept. Treatment with etanercept reduced the frequency of dermal slanDCs but did not induce apoptosis as determined by lack of increased active caspase‐3‐expression. In parallel, we found increased frequencies of slanDCs in blood which expressed lower levels of HLA‐DR. Stimulating slanDCs isolated from the blood of healthy donors in vitro induced a strong production of IL‐1β, IL‐6, IL‐23 and IL‐12p70. This capacity was efficiently reduced in the presence of etanercept, thereby indicating that TNF‐α is an autocrine stimulus for maturation and pro‐inflammatory cytokine production of slanDCs. In vivo, we noticed that treatment with etanercept did reduce the number of dermal slanDCs in parallel to the overall expression of TNF‐α and IL‐23p19. However, successful treatment did not down‐regulated the percentage of dermal slanDCs that stained positive for TNF‐α and IL‐23p19 indicating that remaining slanDCs kept their pro‐inflammatory capacity. This study provides novel insights into the immune regulatory properties of etanercept at the level of inflammatory slanDCs in vivo in skin and blood as well as in vitro. 相似文献
67.
《Expert Review of Clinical Immunology》2013,9(8):837-848
ABSTRACTIntroduction: Biologic therapy has revolutionized the treatment of immune mediated inflammatory diseases (IMID), such as inflammatory bowel disease (IBD), rheumatoid and psoriatic arthritis, ankylosing spondylitis and psoriasis. Nevertheless, some patients exhibit primary nonresponse (PNR) or secondary loss of response (SLR) to biologics.Areas covered: This collaborative review provides data on the role of therapeutic drug monitoring (TDM) in IMID for optimizing biologic therapy including infliximab, adalimumab, certolizumab pegol etanercept and golimumab vedolizumab, secukinumab and ustekinumab.Expert opinion: Most exposure-response relationship studies show a positive correlation between biologic drug concentrations and favorable therapeutic outcomes in IMID with higher drug concentrations typically associated with more objective outcomes. Clinically, reactive TDM rationalizes the management of PNR and SLR to anti-tumor necrosis factor therapy and is emerging as the new standard of care in IBD as it is also more cost-effective than empiric dose escalation. Preliminary data suggest that proactive TDM with the goal to achieve a threshold drug concentration is associated with better therapeutic outcomes when compared to empiric drug optimization and/or reactive TDM of infliximab and adalimumab in IBD. However, more data from well-designed prospective studies are needed to prove the benefit of TDM-based algorithms in real life clinical practice in IMID. 相似文献
68.
TNFα and IL‐17A are differentially expressed in psoriasis‐like vs eczema‐like drug reactions to TNFα antagonists
下载免费PDF全文
![点击此处可从《Journal of cutaneous pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
69.
Adult‐onset inflammatory linear verrucous epidermal nevus (ILVEN) is an uncommon cutaneous disease compared to childhood‐onset ILVEN. The typical histopathologic features are alternating parakeratosis and orthokeratosis with an absent granular layer underneath parakeratosis, in contrast to a thickened granular layer below the foci of orthokeratosis in psoriasiform epidermal hyperplasia. Herein, we present a 49‐year‐old woman with typical clinical and histopathologic characteristics of adult‐onset ILVEN, including linear arrangement of thick scaly papules and plaques localized on the medial side of her right leg, ankle, and foot. Immunohistochemical studies included involucrin, Ki‐67, and keratin‐10. Compared to the staining pattern in psoriasis, the expression of involucrin in this case was of lower intensity and localized to upper epidermal layers with relatively less extensive staining beneath regions of parakeratosis as compared to orthokeratosis; Ki‐67 showed lower basal layer proliferative activity; and keratin‐10 showed a greater intensity of staining within suprabasal epidermis. 相似文献
70.
Shinichi Imafuku Osamu Nemoto Yukari Okubo Mayumi Komine Peter Schafer Rosemary Petric Mamitaro Ohtsuki 《The Journal of dermatology》2021,48(1):80-84
We evaluated the pharmacodynamic effects of apremilast in 69 patients who were included in biomarker subanalyses of a phase 2b study that demonstrated the long‐term safety and efficacy of apremilast in Japanese adults with moderate to severe psoriasis. The association between cytokine levels and Psoriasis Area and Severity Index (PASI) improvement was evaluated using linear regression and Spearman’s rank correlation coefficient analysis. At baseline, median plasma levels of interleukin (IL)‐17A, IL‐17F and IL‐22 were elevated versus reference values for healthy individuals, whereas tumor necrosis factor‐α levels were close to normal. With apremilast 30 mg b.i.d., there were significant associations between percentage change in PASI score and percentage change in IL‐17A, IL‐17F and IL‐22 levels at week 16. Findings demonstrate that the efficacy of apremilast in psoriasis is associated with inhibition of key cytokines involved in the pathology of psoriasis. 相似文献